医学
慢性阻塞性肺病
恶化
肺病
安慰剂
内科学
疾病
物理疗法
重症监护医学
替代医学
病理
标识
DOI:10.1016/s2213-2600(22)00005-4
摘要
The heterogeneity of chronic obstructive pulmonary disease (COPD) means that novel anti-inflammatory treatments might have efficacy only in a subset of individuals. 1 Woodruff PG Agusti A Roche N Singh D Martinez FJ Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet. 2015; 385: 1789-1798 Summary Full Text Full Text PDF PubMed Scopus (167) Google Scholar Phase 2 studies of novel treatments provide an early opportunity to identify responder subgroups, which need to be subsequently confirmed in larger phase 3 studies. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trialIn patients with moderate-to-very severe COPD, astegolimab did not significantly reduce exacerbation rate, but did improve health status compared with placebo. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI